Search Results
Nov 25, 2025, 01:00 ET Fisher Investments anerkendes som et "Great Place to Work®"
globale Fisher-koncern. Fisher Investments Norden er registreret hos det danske finanstilsyn og i det danske selskabsregister, Erhvervsstyrelsen, under CVR-nr. 41000643. Selskabets hjemstedsadresse er: København Ørestad Winghouse, Ørestads Boulevard 73, 2300 København S, Danmark. Den danske filial af Fisher
More news about: Fisher Investments Norden
Nov 19, 2025, 18:18 ET Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones. If you are an Adverum shareholder,
More news about: Halper Sadeh LLP
Nov 19, 2025, 14:10 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferable contingent value right ("CVR") entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones.
More news about: Monteverde & Associates PC
Nov 19, 2025, 06:00 ET Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
one (1) non-transferable contingent value right ("CVR") entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final U.S. Food and Drug Administration ("FDA") LUMRYZ™ Approval (as defined in the form of CVR agreement to be entered into by Alkermes and
More news about: Alkermes plc
Nov 18, 2025, 11:38 ET CHICAGO RIVET & MACHINE CO. DECLARES DIVIDEND
WARRENVILLE, Ill., Nov. 18, 2025 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE American: CVR) today announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share payable December 19, 2025, to all shareholders of
More news about: Chicago Rivet & Machine Co.
Nov 14, 2025, 19:56 ET Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages
More news about: Ademi LLP
Nov 14, 2025, 15:19 ET Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights
transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up to $55.25 per share in cash. If you are a Mersana shareholder,
More news about: Halper Sadeh LLP
Nov 13, 2025, 06:59 ET Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CVR liability
More news about: Q32 Bio
Nov 10, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferable contingent value right ("CVR") entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones.
More news about: Monteverde & Associates PC
Nov 10, 2025, 08:00 ET Johnson & Johnson lança plataforma VARIPULSE™ no Brasil e avança no tratamento da fibrilação atrial
GMC, Coats AJSC. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272–3287. doi:10.1093/cvr/cvac013 xiv American Heart Association . (2024, August 12). What are the symptoms of atrial fibrillation?.
More news about: Johnson & Johnson MedTech
Nov 10, 2025, 06:55 ET TreeHouse Foods and Investindustrial Announce Definitive Acquisition Agreement for a Total Enterprise Value of $2.9 Billion
will receive $22.50 per share in cash for each share of common stock owned at closing, and one non-transferable Contingent Value Right ("CVR") per common share. The CVR generally will provide a holder with an opportunity to receive certain net proceeds, if any are recovered, from certain ongoing litigation
More news about: TreeHouse Foods, Inc.
Nov 07, 2025, 21:32 ET Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash. The Metsera Board of Directors has determined that
More news about: Metsera, Inc.
Nov 07, 2025, 16:45 ET Chicago Rivet & Machine Co. Announces Third Quarter Results of Operations
WARRENVILLE, Ill., Nov. 7, 2025 /PRNewswire/ -- Chicago Rivet & Machine Co. (NYSE: CVR) today announced results for the third quarter of 2025 as summarized below:
More news about: Chicago Rivet & Machine Co.
Nov 05, 2025, 08:00 ET Icahn Enterprises L.P. (Nasdaq: IEP) Today Announced Its Third Quarter 2025 Financial Results
CVR Energy(2)
More news about: Icahn Enterprises L.P.
Nov 04, 2025, 09:30 ET Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"
from $47.50) and decreased the amount payable under the CVR to up to $10.00 per share in cash (down from $22.50). In addition, the Revised Pfizer Proposal (i) adopted the same commercially reasonable efforts standard for the CVR as in the Novo Nordisk Proposal, (ii) required a shareholder
More news about: Metsera, Inc.
Oct 30, 2025, 07:07 ET Metsera Receives Unsolicited Proposal from Novo Nordisk
happen only after receiving approval from Metsera shareholders and relevant regulators, Metsera shareholders would receive a contingent value right ("CVR") representing up to $21.25 per share in cash based on development and regulatory approval milestones substantially similar to those agreed in the proposed
More news about: Metsera, Inc.
Oct 27, 2025, 13:01 ET HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferrable contingent value right (CVR) entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones. If you are an Adverum shareholder,
More news about: Halper Sadeh LLP
Oct 24, 2025, 17:30 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
transaction, Adverum shareholders will receive $3.56 per share in cash plus one non-transferable contingent value right ("CVR") entitling the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two certain milestones. Is it a fair deal?
More news about: Monteverde & Associates PC
Oct 24, 2025, 14:23 ET VISION26 Brings AI Insights & CME Opportunity to Washington, DC
Restoration Center for Vein Restoration (CVR) is the nation's largest physician-led vein center, with 120+ clinics and 80+ board-certified physicians nationwide. CVR leads in the diagnosis and treatment of venous and lymphatic disorders through innovation,
More news about: Center for Vein Restoration
Oct 24, 2025, 08:30 ET Lilly to Acquire Adverum Biotechnologies
non-transferrable contingent value right (CVR) that entitles the holder to receive up to an additional $8.91 per CVR in cash upon the achievement of two milestones described below, for total potential per share consideration of up to $12.47. The CVR provides payments if and when the
More news about: Eli Lilly and Company
Oct 22, 2025, 07:00 ET Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
of the CVR Agreement. The CVRs are intended to afford Company Shareholders an opportunity to benefit from the achievement of the Milestone in accordance with the terms of the CVR Agreement. Subject and pursuant to the terms of the CVR Agreement, each CVR will represent
More news about: Alkermes plc; Avadel Pharmaceuticals plc
Oct 16, 2025, 09:00 ET Acron Aviation and Airbus Join Forces to Offer an Upgrade Solution for 25-Hour CVR
Acron Aviation's 25-hour Cockpit Voice Recorder (CVR), marketed as SRVIVR25, is Airbus' chosen solution for 25-hour CVR with recording capability. SRVIVR25, the only 25-hour CVR approved and qualified by Airbus thus far, is fully compliant with the Federal Aviation
More news about: Acron Aviation
Oct 16, 2025, 09:00 ET Acron Aviation and Airbus Join Forces to Offer an Upgrade Solution for 25-Hour CVR
Acron Aviation's 25-hour Cockpit Voice Recorder (CVR), marketed as SRVIVR25, is Airbus' chosen solution for 25-hour CVR with recording capability. SRVIVR25, the only 25-hour CVR approved and qualified by Airbus thus far, is fully compliant with the Federal Aviation
More news about: Acron Aviation
Oct 09, 2025, 07:00 ET ESSA Announces Completion of Arrangement with XenoTherapeutics
US$0.1242 per Common Share, plus one contingent value right ("CVR") per Common Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Acquisition. The potential CVR payment of US$0.14 per Common Share represents up to
More news about: ESSA Pharma Inc
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
the financing shall be subject to stockholder approval in compliance with the rules of the Nasdaq Stock Market where applicable. A non-transferrable CVR will be distributed to TransCode stockholders of record as of October 20, 2025 to receive certain proceeds received by TransCode, if any, related to
More news about: TransCode Therapeutics, Inc.